InvestorsHub Logo
Followers 7
Posts 781
Boards Moderated 0
Alias Born 10/26/2021

Re: DreyDreyDrey post# 12813

Friday, 10/14/2022 12:43:28 PM

Friday, October 14, 2022 12:43:28 PM

Post# of 20567
Todos isn't selling part of their 52%. 3CL Pharma was independently assessed and valued at $1.9B. They won't be trying to raise that much. They wouldn't want to sell that many shares, but only sell enough to fund their initiatives and operating costs until revenues are sufficient to cover all of this.

It has not been determined yet if shareholders will get individual shares in the spinoff. One could assume if that's the case, that part may come out of Todos 52% ownership portion. It makes sense the final ratio of ownership will be spread among Todos, 3CL Pharma, and outside investors participating in the capital raise, so that the combined ownership of all 3 equals 100% of the existing share structure at the spinoff. Todos percentage should drop, but they should still have the majority ownership position.

The key point in my mind is that Todos has the option to acquire 100% of the new entity and has the share structure in place to make that happen, but this only makes sense after the uplist to NYSE.